Cullinan Therapeutics, Inc. (CGEM) vs Corvus Pharmaceuticals, Inc. (CRVS)
A side-by-side comparison of Cullinan Therapeutics, Inc. and Corvus Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CGEM
Cullinan Therapeutics, Inc.
$16.41HealthcareDelayed quote: Oct 6, 2026, 2:00 PM EDT
CRVS
Corvus Pharmaceuticals, Inc.
$10.31HealthcareDelayed quote: Oct 6, 2026, 2:00 PM EDT
Total return — CGEM vs CRVS
growth of $100 · dividends reinvested · last 6yCGEM -46.4% (-9.9%/yr)CRVS +181.2% (+18.8%/yr)CRVS compounded faster over this window
Log scale — wide-divergence pair
CGEM CRVS
CGEM vs CRVS: by the numbers
- •CGEM is the larger company ($1.01B vs $867M market cap).
Metrics side by side
Valuation
| Metric | CGEM | CRVS |
|---|---|---|
| P/B ratio | 3.13 | 3.85 |
Profitability
| Metric | CGEM | CRVS |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -63.62% | -24.02% |
| ROIC | -68.64% | -25.25% |
Growth (annualized)
| Metric | CGEM | CRVS |
|---|---|---|
| Total return CAGR (5Y) | -7.48% | 17.88% |
Frequently asked
- How have CGEM and CRVS total returns compared?
- Over the past 5 years, CGEM delivered -7.48% and CRVS delivered 17.88% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.